Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Int J Tuberc Lung Dis ; 17(11): 1402-4, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24125441

ABSTRACT

SETTING: Between 2005 and 2008, the diagnosis and care of human immunodeficiency virus (HIV) infection and tuberculosis (TB) services were integrated in Benin. RESULTS: The appointment of a TB-HIV Coordinator by the National Tuberculosis Control Programme and quarterly supervisory visits to TB clinics have bolstered the implementation of integrated HIV-TB activities. HIV testing and cotrimoxazole preventive therapy were integrated smoothly into the TB services. The strategy chosen to facilitate access of HIV-positive TB patients to antiretroviral treatment contributed to greater integration over time, but perpetuated, for some, the burden of attending two facilities. CONCLUSION: The integration and decentralisation of TB and HIV care services at national level in Benin resulted in a high uptake of HIV services among TB patients.


Subject(s)
Antitubercular Agents/therapeutic use , Coinfection , Delivery of Health Care, Integrated , HIV Infections/diagnosis , Tuberculosis/drug therapy , Anti-HIV Agents/therapeutic use , Benin/epidemiology , Cooperative Behavior , Counseling , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/prevention & control , Health Services Accessibility , Health Services Needs and Demand , Humans , Interdisciplinary Communication , Interinstitutional Relations , Patient Acceptance of Health Care , Predictive Value of Tests , Program Development , Program Evaluation , Time Factors , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Tuberculosis/diagnosis , Tuberculosis/epidemiology
2.
Int J Tuberc Lung Dis ; 17(11): 1405-10, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24125442

ABSTRACT

SETTING: Benin, where 20 of 54 tuberculosis (TB) clinics caring for 80% of all TB patients began providing integrated human immunodeficiency virus (HIV) care in 2005. OBJECTIVE: To describe the characteristics and TB treatment outcomes of the first cohorts of TB-HIV patients, and to assess programmatic outcomes. METHODS: Retrospective cohort study using data from the TB register and the register of co-infected patients. RESULTS: During the study period, 8368 TB patients were registered, 7787 (93%) were tested for HIV and 1255 (16%) were HIV-positive, including 385 (32%) who already knew their positive status. Most patients (88%) were tested within 15 days of TB diagnosis. Female and young patients were overrepresented among the co-infected. Cotrimoxazole preventive therapy was administered to 1152 patients (95%) during anti-tuberculosis treatment, and antiretroviral treatment (ART) to 469 (42%). The likelihood of receiving ART increased as initial CD4 lymphocyte counts decreased. Fifteen per cent of TB-HIV patients died during anti-tuberculosis treatment. Patients already on ART prior to anti-tuberculosis treatment experienced the worst outcomes. Patients who initiated ART early during anti-tuberculosis treatment or in the timeframe recommended by the guidelines fared the best. CONCLUSION: HIV care has been successfully and sustainably integrated into TB services in Benin. However, ensuring the access of co-infected patients to more favourable treatment outcomes still represents significant challenges.


Subject(s)
Anti-HIV Agents/therapeutic use , Antitubercular Agents/therapeutic use , Coinfection , Delivery of Health Care, Integrated , HIV Infections/diagnosis , HIV Infections/drug therapy , Tuberculosis/drug therapy , Adolescent , Adult , Aged , Benin/epidemiology , Counseling , Female , HIV Infections/epidemiology , HIV Infections/prevention & control , Health Services Accessibility , Health Services Needs and Demand , Humans , Male , Middle Aged , Predictive Value of Tests , Program Development , Program Evaluation , Registries , Retrospective Studies , Time Factors , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Tuberculosis/diagnosis , Tuberculosis/epidemiology , Young Adult
3.
Int J Tuberc Lung Dis ; 13(8): 927-35, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19723371

ABSTRACT

Isoniazid preventive therapy (IPT) is recognised as an important component of collaborative tuberculosis (TB) and human immunodeficiency virus (HIV) activities to reduce the burden of TB in people living with HIV (PLHIV). However, there has been little in the way of IPT implementation at country level. This failure has resulted in a recent call to arms under the banner title of the 'Three I's' (infection control to prevent nosocomial transmission of TB in health care settings, intensified TB case finding and IPT). In this paper, we review the background of IPT. We then discuss the important challenges of IPT in PLHIV, namely responsibility and accountability for the implementation, identification of latent TB infection, exclusion of active TB and prevention of isoniazid resistance, length of treatment and duration of protective efficacy. We also highlight several research questions that currently remain unanswered. We finally offer practical suggestions about how to scale up IPT in the field, including the need to integrate IPT into a package of care for PLHIV, the setting up of operational projects with the philosophy of 'learning while doing', the development of flow charts for eligibility for IPT, the development and implementation of care prior to antiretroviral treatment, and finally issues around procurement, distribution, monitoring and evaluation. We support the implementation of IPT, but only if it is done in a safe and structured way. There is a definite risk that 'sloppy' IPT will be inefficient and, worse, could lead to the development of multidrug-resistant TB, and this must be avoided at all costs.


Subject(s)
Antitubercular Agents/therapeutic use , HIV Infections/epidemiology , Isoniazid/therapeutic use , Tuberculosis/epidemiology , Tuberculosis/prevention & control , Comorbidity , Drug Resistance, Microbial , Global Health , Humans , Public Health
4.
Int J Tuberc Lung Dis ; 11(7): 755-61, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17609050

ABSTRACT

BACKGROUND: Little is known yet about the cost-effectiveness of public-private mix (PPM) collaborations for the delivery of tuberculosis (TB) diagnostic and treatment services. DESIGN: We evaluated the cost and cost-effectiveness of a PPM project targeting private laboratories in Kannur district, India, from the perspective of the Revised National TB Control Programme (RNTCP). We estimated the cost per provider recruited and retained, the cost per additional patient notified under various effectiveness scenarios and the cost per additional patient successfully treated. Intervention cost data were abstracted from RNTCP records. Treatment costs were estimated based on RNTCP case management protocols. RESULTS: The annual total estimated cost of the project was US$8712-$11611. The cost per private provider recruited varied between US$22 and US$54. The cost per additional pulmonary TB patient privately diagnosed was US$14-$18. In the most conservative scenario, the cost per additional patient notified was US$29-$36. The cost per new acid-fast bacilli-positive patient successfully treated was US$47-$51. Higher notification rates would improve cost-effectiveness. CONCLUSIONS: Comparisons with public sector diagnostic costs are required to determine if this intervention remains economically attractive to the public health care system at different activity levels and to determine the supplemental resources needed if scale-up is pursued.


Subject(s)
Communicable Disease Control/economics , Cost of Illness , National Health Programs/organization & administration , Public-Private Sector Partnerships/organization & administration , Tuberculosis, Pulmonary/economics , Cost-Benefit Analysis , Costs and Cost Analysis , Developing Countries , Female , Financing, Organized/economics , Humans , India , Male , Program Evaluation , Registries , Retrospective Studies , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/therapy
5.
Int J Tuberc Lung Dis ; 9(2): 145-50, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15732732

ABSTRACT

SETTING: In resource-poor countries, few tuberculosis (TB) program staff at the national, provincial, and even district levels have the basic analytical and epidemiological skills necessary for collecting and analyzing quality data pertaining to national TB control program (NTP) improvements. This includes setting program priorities, operations planning, and implementing and evaluating program activities. OBJECTIVES: To present a model course for building capacity in basic epidemiology and operations research (OR). DESIGN: A combination of didactic lectures and applied field exercises were used to achieve the main objectives of the 6-day OR course. These were to increase the understanding of quantitative and qualitative research concepts, study design, and analytic methods, and to increase awareness of how these methods apply to the epidemiology and control of TB; and to demonstrate the potential uses of OR in answering practical questions on NTP effectiveness. As a final outcome, course participants develop OR proposals that are funded and later implemented. RESULTS: Since 1997, this OR course has been conducted nine times in five countries; 149 key NTP and laboratory staff have been trained in OR methods, and 44 OR protocols have been completed or are underway. CONCLUSION: This low-cost model course can be adapted to a wide range of public health issues.


Subject(s)
National Health Programs , Operations Research , Public Health/education , Tuberculosis/prevention & control , Health Priorities
SELECTION OF CITATIONS
SEARCH DETAIL
...